Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07458425 · ClinicalTrials.gov registry record · NA
The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk
A NA study, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
NCT07458425 is a NA study that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 400 participants.
The verdict
NCT07458425, a NA study, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
Study Summary
This is a two-cohort (screen naïve vs screen established), prospective, longitudinal, single-center clinical study design that will provide data to comprehensively evaluate patient-reported outcomes of Artificial Intelligence (AI) based prediction of an individual's risk of developing lung cancer over the next 3 years.
Interventions
- DIAGNOSTIC_TEST Artificial Intelligence (AI) test
- DIAGNOSTIC_TEST Research-use-only multimodal AI risk model
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-03-11 |
| Est. Completion | 2029-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07458425
The ClinicalTrials.gov registry entry for NCT07458425 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Artificial Intelligence (AI) test is the first listed.
NCT07458425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07458425 about?
NCT07458425 is a clinical study titled "The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk". This is a two-cohort (screen naïve vs screen established), prospective, longitudinal, single-center clinical study design that will provide data to comprehensively evaluate patient-reported outcomes of Artificial Intelligence (AI) based prediction of an individual's risk of developing lung cancer ov...
What is the current status of trial NCT07458425?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2026-03-11. Estimated completion is 2029-01.
What interventions are being tested in trial NCT07458425?
The interventions under investigation include: Artificial Intelligence (AI) test (DIAGNOSTIC_TEST), Research-use-only multimodal AI risk model (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07458425?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.